China Biopharmaceutical Cmo And Cro Market Size & Outlook

The biopharmaceutical cmo and cro market in China is expected to reach a projected revenue of US$ 4,885.7 million by 2030. A compound annual growth rate of 3.6% is expected of China biopharmaceutical cmo and cro market from 2022 to 2030.
Revenue, 2021 (US$M)
$3,566.6
Forecast, 2030 (US$M)
$4,885.7
CAGR, 2022 - 2030
3.6%
Report Coverage
China

China biopharmaceutical cmo and cro market highlights

  • The China biopharmaceutical cmo and cro market generated a revenue of USD 3,566.6 million in 2021 and is expected to reach USD 4,885.7 million by 2030.
  • The China market is expected to grow at a CAGR of 3.6% from 2022 to 2030.
  • In terms of segment, mammalian was the largest revenue generating source in 2021.
  • Non-mammalian is the most lucrative source segment registering the fastest growth during the forecast period.


Biopharmaceutical cmo and cro market data book summary

Market revenue in 2021USD 3,566.6 million
Market revenue in 2030USD 4,885.7 million
Growth rate3.6% (CAGR from 2021 to 2030)
Largest segmentMammalian
Fastest growing segmentNon-mammalian
Historical data2017 - 2020
Base year2021
Forecast period2022 - 2030
Quantitative unitsRevenue in USD million
Market segmentationMammalian, Non-mammalian
Key market players worldwideBoehringer Ingelheim, Lonza Group Ltd, Innovent Biologics Inc, Rentschler Biopharma SE, JRS Pharma, AGC Inc, Probiogen, FUJIFILM Holdings Corp, Toyobo Co Ltd, Samsung BioLogics, Thermo Fisher Scientific Inc, R1 RCM Inc, WuXi Biologics (Cayman) Inc, AbbVie Inc, Binex, Charles River Laboratories International Inc, Icon PLC, PAREXEL, Labcorp Holdings Inc


Other key industry trends

  • In terms of revenue, China accounted for 12.1% of the global biopharmaceutical cmo and cro market in 2021.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Asia Pacific, India biopharmaceutical cmo and cro market is projected to lead the regional market in terms of revenue in 2030.
  • India is the fastest growing regional market in Asia Pacific and is projected to reach USD 6,632.0 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Biopharmaceutical CMO And CRO Market Companies

Name Profile # Employees HQ Website

China biopharmaceutical cmo and cro market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biopharmaceutical cmo and cro market will help companies and investors design strategic landscapes.


Mammalian was the largest segment with a revenue share of 54.91% in 2021. Horizon Databook has segmented the China biopharmaceutical cmo and cro market based on mammalian, non-mammalian covering the revenue growth of each sub-segment from 2017 to 2030.


This country is expected to benefit significantly by the local presence of prominent market leaders. For instance, in December 2018, Lonza signed an agreement with GE Healthcare, as per the agreement GE Healthcare provided a biologics manufacturing facility of Lonza to support the manufacturing of biopharmaceuticals in the country.

Increase in outsourcing of operations to Chinese market players by overseas biopharma firms is recognized as the major driver for the Chinese CMO & CRO market. Global innovator companies outsource a significant portion of their research to restructure R&D and cut costs.

Furthermore, biotechnology and its related aspects are significantly funded by the Chinese government. Regulatory changes to enhance safe & effective usage and rapid development of drugs in China are expected to positively influence the market growth.

Reasons to subscribe to China biopharmaceutical cmo and cro market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of China biopharmaceutical cmo and cro market databook

  • Our clientele includes a mix of biopharmaceutical cmo and cro market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the China biopharmaceutical cmo and cro market , including forecasts for subscribers. This country databook contains high-level insights into China biopharmaceutical cmo and cro market from 2017 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

China biopharmaceutical cmo and cro market size, by source, 2017-2030 (US$M)

China Biopharmaceutical CMO And CRO Market Outlook Share, 2021 & 2030 (US$M)

China biopharmaceutical cmo and cro market size, by source, 2017-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more